Citius Oncology Inc.
CTOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.2M
Close$
$0.00
99.8% downside
Current Fair Value
99.8% downsideOvervalued by 99.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $74.20 Million |
|---|---|
| Enterprise Value | $75.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.34 |
| Beta | 3.58 |
| Outstanding Shares | 100,027,204 |
Return
| Return on Equity | -120.53% |
|---|---|
| Return on Assets | -42.22% |
| Return on Invested Capital | -103.75% |
Valuation & Multiples
| P/E Ratio | -1.88 |
|---|---|
| PEG | -0.77 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 13.43 |
| Enterprise Value to EBIT | -1.73 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$7.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$5.83 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.24%▲ 6.40% |
|---|---|
| Total Invested | $8.83M▲ 28.68% |
| Investors Holding | 13▼ 4.00% |
ESG Score
No data